Hepatitis A - Pipeline Review, H1 2018

  • ID: 4515994
  • Report
  • 26 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Cadila Healthcare Ltd
  • Indian Immunologicals Ltd
  • Sinovac Biotech Ltd
  • MORE
Hepatitis A - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis A - Pipeline Review, H1 2018, provides an overview of the Hepatitis A (Infectious Disease) pipeline landscape.

Hepatitis A is inflammation of the liver caused by hepatitis A virus. Symptoms include fatigue, nausea and vomiting, inflammation of the liver, loss of appetite, dark urine, muscle pain and yellowing of the skin and eyes (jaundice). Risk factors include weakened immune system and use injected or non-injected illicit drugs. Treatment includes antiemetics and pain relievers.

Report Highlights:

This latest Pharmaceutical and Healthcare disease pipeline guide pipeline guide Hepatitis A - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Hepatitis A (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatitis A (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis A and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, IND/CTA Filed and Preclinical stages are 2, 1, 1 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Hepatitis A (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researechers' proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis A (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Hepatitis A (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hepatitis A (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hepatitis A (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis A (Infectious Disease)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hepatitis A (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hepatitis A (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Cadila Healthcare Ltd
  • Indian Immunologicals Ltd
  • Sinovac Biotech Ltd
  • MORE
Introduction

Report Coverage

Hepatitis A - Overview

Hepatitis A - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Hepatitis A - Therapeutics Assessment

Assessment by Route of Administration

Assessment by Molecule Type

Hepatitis A - Companies Involved in Therapeutics Development

Beijing Minhai Biotechnology Co Ltd

Cadila Healthcare Ltd

China National Pharmaceutical Group Corp

Indian Immunologicals Ltd

Sinovac Biotech Ltd

Hepatitis A - Drug Profiles

hepatitis A + hepatitis B vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hepatitis A vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hepatitis A vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hepatitis A vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hepatitis A vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hepatitis A vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hepatitis A - Dormant Projects

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Hepatitis A, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Hepatitis A - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2018

Hepatitis A - Pipeline by Cadila Healthcare Ltd, H1 2018

Hepatitis A - Pipeline by China National Pharmaceutical Group Corp, H1 2018

Hepatitis A - Pipeline by Indian Immunologicals Ltd, H1 2018

Hepatitis A - Pipeline by Sinovac Biotech Ltd, H1 2018

Hepatitis A - Dormant Projects, H1 2018

List of Figures

Number of Products under Development for Hepatitis A, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Beijing Minhai Biotechnology Co Ltd
  • Cadila Healthcare Ltd
  • China National Pharmaceutical Group Corp
  • Indian Immunologicals Ltd
  • Sinovac Biotech Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll